Skip to main content
Figure 6 | Molecular Cancer

Figure 6

From: HMGN2, a new anti-tumor effector molecule of CD8+ T cells

Figure 6

T-Ag activated CD8+T cells released HMGN2 to kill tumor cells. PBMCs were seeded at a density of 1 × 107 per well in 6 well plates and stimulated with 150 μg/ml T-Ag for 7 days. (A) Cells were removed and stained with CD44-APC/CD8-FITC. CD44high/CD8+T activated T cells (Gate R4) were purified with MoFlo XDP sorter. The purified CD44high/CD8+T cells were cultured in complete medium with 2000 IU/ml IL-2 for 5 days. (B) The cells were removed and stained with Anti-CD8-PE surface stained and anti-HMGN2/IgG-FITC intracellular stained. (C) The antitumor effects of the supernatants at different concentration. (D) The antitumor effects of the 20% (v/v) supernatants after blocking HMHN2 using anti-HMGN2 antibody. Figures are representative of three independent experiments. Data are represented as means ± SD of three independent experiments. *Significantly decreased compared to medium control (p < 0.05). #Significantly decreased after with anti-HMGN2 antibody (p < 0.05).

Back to article page